mRNA Melanoma Trial Simulator KEYNOTE-942 Benchmark

Neoantigen Immune Synapse & Micro-Clearance

Active Synapse
Lipid nanoparticles deliver 34 synthetic neoantigen payloads to dendritic cells. HLA class I presentation triggers robust clonal expansion of cytotoxic CD8+ T-cells, neutralizing micrometastatic melanoma foci.
CD8+ Cytotoxic Index 92
LNP Transfection Rate 94.8%
Foci Clearance Rate 89.2%

Kaplan-Meier Recurrence-Free Survival (RFS)

mRNA-4157 + Pembro
Pembro Monotherapy
Hazard Ratio (HR) 0.56
Risk Reduction 44%
Combo 36-Mo RFS 78.4%
Control 36-Mo RFS 62.1%
Median RFS (Combo) Not Reached (>36 mo)
Enjoy this tool? Build your own with Super